Use of Weekly One Hour Paclitaxel Infusion With Dose Escalation for Recurrent and Resistant Cancers, Using Amifostine as a Cytoprotector
OBJECTIVES: I. Determine the maximum tolerated dose of weekly paclitaxel following
amifostine in patients with recurrent or refractory solid tumors. II. Assess tumor response
rate and survival in these patients.
OUTLINE: This is a dose escalation study of paclitaxel. Patients receive amifostine IV over
5 minutes or less on day 0, followed by paclitaxel IV over 1 hour once a week for 6 weeks
followed by 2 weeks of rest. Patients with complete or partial response may receive
additional courses of therapy. Cohorts of 3-5 patients each receive increasing doses of
paclitaxel. The maximum tolerated dose is defined as the dose level prior to the cohort at
which 1 of 3-5 patients experience dose limiting toxicity.
PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.
Primary Purpose: Supportive Care
Jonathan Wright, MD
State University of New York - Upstate Medical University
United States: Federal Government
|State University of New York - Upstate Medical University||Syracuse, New York 13210|